公开(公告)号：EP3193877A1

公开(公告)日：2017-07-26

申请号：EP15829513.9

申请日：2015-08-07

申请人： Pharmacyclics LLC

发明人： TAY, Pearl Shwe-Cho ,  MINIKIS, Ryan Mitchell ,  HULVAT, James Francis ,  MCVEY, Alexander Jacob ,  SHU, Cassandra ,  ATLURI, Harisha ,  KUEHL, Robert ,  CHONG, Ching Wah

IPC分类号： A61K31/519 ,  C07D487/04 ,  A61K9/26

CPC分类号： A61K31/519 ,  A61K9/10 ,  A61K9/146 ,  A61K9/1652 ,  A61K9/2054 ,  A61K9/2077 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38

摘要： Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

摘要翻译： 本文描述了布鲁顿氏酪氨酸激酶（Btk）抑制剂1 - （（R）-3-（4-氨基-3-（4-苯氧基苯基）-1H-吡唑并[3,4-d]嘧啶-1-基）哌啶 -1-基）丙-2-烯-1-酮，包括其新药物制剂。 还公开了包含Btk抑制剂的药物组合物，以及单独或与其他治疗剂组合使用Btk抑制剂用于治疗自身免疫疾病或病症，异质性免疫疾病或病症，癌症，包括淋巴瘤和 炎性疾病或病症。